Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.

Slides:



Advertisements
Similar presentations
Figure 2 ERG amplitude reduction in the follow-up study
Advertisements

Figure 3 Methodological strategy, flow cytometric analysis, cytokine profile, and clonality of brain-infiltrating cells Methodological strategy, flow cytometric.
Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.
Figure Seropositivity for IgG against HSV-1, CMV, and EBV
Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.
Figure 1 Box plot of the venous diameter in lesions
Figure 3 Test reliability of enzymatic dissociation methods
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure Muscle biopsy of the left biceps showing the characteristic pathologic findings in BCIM Muscle biopsy of the left biceps showing the characteristic.
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.
Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,
Figure 1 Histopathologic features of case 1 (A–G) and case 2 (H–L)‏
Figure 1 Quantitative spinal cord MRI maps and segmentations
Figure 2 Neuropathology of PML lesions in a patient with MS treated with fingolimod Neuropathology of PML lesions in a patient with MS treated with fingolimod.
Figure 3 Gene expression in CSF cell pellets
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure Association of hippocampal subfield volumes to cognition by neopterin level, volumes, and cognition adjusted for age, education, race, sex, and.
Figure 2 Histopathologic findings of patients with both inflammatory myopathy and myasthenia gravis Histopathologic findings of patients with both inflammatory.
Figure MRI and neuropathologic characteristics of the tumefactive demyelinating lesion in our patient MRI and neuropathologic characteristics of the tumefactive.
Figure 1 Sections of muscle biopsy specimens stained with hematoxylin & eosin (HE)‏ Sections of muscle biopsy specimens stained with hematoxylin & eosin.
Figure 1 Characteristics of the German National MS Cohort
Figure 2 Linkage analysis of chromosome 19
Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.
Figure 3 Detection of JC virus (JCV) genomic DNA in mildly enlarged nuclei of oligodendroglia-like cells Detection of JC virus (JCV) genomic DNA in mildly.
Figure 1 Illustration of white matter– and lesion-associated regions of interest (ROIs)‏ Illustration of white matter– and lesion-associated regions of.
Figure 3 Analysis of the prognostic value of IL-10–producing B cells or IL-6/IL-10–B-cell ratio measurements in patients with RIS/CIS MS Analysis of the.
Table 2 Rs number, gene, OR, 95% CI, and permutation p value for the statistical significant variants resulted from allelic association analysis association.
Figure Alluvial plot of modified Rankin Scale (mRS) scores during and at the end of hospital stay Alluvial plot of modified Rankin Scale (mRS) scores during.
Figure 4 Leukocyte subset isolation from brain tissue by enzymatic dissociation Leukocyte subset isolation from brain tissue by enzymatic dissociation.
Figure 3 Comparisons of quantitative spinal cord MRI measures and brain atrophy in RIS vs. healthy controls (adjusted for age and sex)‏ Comparisons of.
Figure 1 Phenotype and functional properties of B cells in MS and HCs at baseline Phenotype and functional properties of B cells in MS and HCs at baseline.
Figure 1 Proportions of the major B-cell subsets in DMF-treated patients Proportions of the major B-cell subsets in DMF-treated patients B cells were collected.
Figure 1 Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation (A) Western.
Figure 6 Cellular composition after tissue dissociation
Figure 2 Immunohistological detection of EBV latent and early lytic proteins in MS and control brains Immunohistological detection of EBV latent and early.
Figure 2 Longitudinal relationship between CSF glucose and protein changes Longitudinal relationship between CSF glucose and protein changes Delta glucose.
Figure Forty-two months of follow-up of clinical symptoms in parallel with therapeutic interventions and antibody titers/B-cell count Forty-two months.
Figure 1 Annualized percentage brain volume change
Figure 2 BVL according to on-study disability worsening
Figure 2 Repopulation of CD19+ cells in low and high BSA patients and calculation of the BSA Repopulation of CD19+ cells in low and high BSA patients and.
Figure 2 Frequency of the proportion of total WMLs with central veins in PPMS, RRMS, and SVD Frequency of the proportion of total WMLs with central veins.
Figure 2 Brain biopsy of 2 patients with anti-MOG encephalitis initially misdiagnosed with small vessel CNS vasculitis Brain biopsy of 2 patients with.
Figure 1 (A–D) Nuclear factor (erythroid-derived 2)-like 2–related transcripts are increased 6 weeks after treatment in responders but not in nonresponders.
Figure 2 Seizure outcomes
Figure 2 Overview of apheresis therapies
Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521
Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504
Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453
Figure 1 Analysis of inflammatory cells in muscle biopsies
Figure 1 Imaging and histopathologic characteristics of patients with CNS-FHL Imaging and histopathologic characteristics of patients with CNS-FHL FLAIR.
Figure 1 Tissue processing methods and cellular viability
Figure 3 C5B3 blocked MAC formation
Figure 3 Within-group comparisons (before–after)‏
Figure 1 Segmentation of the normal-appearing periependymal white matter Segmentation of the normal-appearing periependymal white matter The figure demonstrates.
Figure 5 C5B3 inhibited inflammatory infiltration in an NMOSD mouse model in vivo C5B3 inhibited inflammatory infiltration in an NMOSD mouse model in vivo.
Figure 2 Time from incident ADS event to MS diagnosis
Figure 2 Nonhuman primate brain immunohistochemistry
Figure 4 Venn diagram for B-cell Sup proteins compared with proteins from exosome-enriched fractions from a human B-cell line Venn diagram for B-cell Sup.
Figure 3 A receiver operating characteristic curve of days to IVMP as a predictor of failure to regain 0.2 logMAR (20/30) vision (AUC 0.84, p < 0.001)‏
Figure 2 Correlations of subcortical gray matter SUVRs with the EDSS score, T25FW, and BPV in MS Correlations of subcortical gray matter SUVRs with the.
Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.
Presentation transcript:

Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Formalin-fixed paraffin embedded brain tissue from MS and control brains without neurologic disease were cut into 4-μm sections. Hematoxylin and eosin (H&E) and immunohistochemistry were performed using antibodies against latent membrane protein 1 (LMP-1), Epstein-Barr virus (EBV) immediate-early lytic gene (BZLF1), and Syndecan-1 (CD138), a plasma cell marker. For each MS and control sample, the number of CD138+, LMP-1+, and BZLF1+ cells with a visible nucleus was counted manually to allow semiquantitative analysis and categorization of these markers. Results are semiquantitative and expressed as percentage of patients expressing as no cells/mm2, <5 cells/mm2, 5–10 cells/mm2, and >10 cells/mm2 (A–C). Semiquantitative analysis of CD138 (D) and EBV antigen-positive cells (E,F) in MS and healthy control samples (D-F). CD138+ cells in MS and control samples were characterized by their location in perivascular regions or in the parenchyma (G and H), revealing an increased frequency of parenchymal CD138+ cells in CAPs and CPs vs controls (H). The number of cells was counted from samples (MS: n = 11 autopsy samples and n = 6 biopsy samples; controls samples: n = 9 autopsy samples n = 0 biopsy samples). The number of cells was counted on 3 × 3-cm autopsy sections and on 2 × 2-cm sections for biopsy samples. Monica A. Moreno et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e466 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.